Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies1393
  • 7D-0.2%
  • 3M-5.3%
  • 1Y12.7%
  • YTD-3.8%

Over the last 7 days, the Healthcare industry has remained flat, although notably Revolution Medicines gained 58%. As for the the longer term, the industry is up 13% over the past 12 months. Looking forward, earnings are forecast to grow by 17% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026US$6.3tUS$3.3tUS$121.4b23.7x52x1.9x
Sat, 14 Mar 2026US$6.2tUS$3.3tUS$124.5b24.3x50x1.9x
Mon, 09 Feb 2026US$6.6tUS$3.3tUS$125.4b27.1x52.4x2x
Wed, 07 Jan 2026US$6.5tUS$3.2tUS$135.6b26.3x47.8x2x
Fri, 05 Dec 2025US$6.4tUS$3.2tUS$133.6b26x48.2x2x
Sun, 02 Nov 2025US$6.0tUS$3.1tUS$134.4b26.1x44.4x1.9x
Tue, 30 Sep 2025US$5.7tUS$3.1tUS$137.6b23.4x41.1x1.8x
Thu, 28 Aug 2025US$5.7tUS$3.1tUS$137.2b23.4x41.5x1.8x
Sat, 26 Jul 2025US$5.6tUS$3.0tUS$129.3b24.6x43.1x1.8x
Mon, 23 Jun 2025US$5.4tUS$3.0tUS$127.5b24x42.5x1.8x
Wed, 21 May 2025US$5.5tUS$3.0tUS$126.1b24x43.2x1.8x
Fri, 18 Apr 2025US$5.3tUS$2.6tUS$97.6b24.8x54.3x2x
Sun, 16 Mar 2025US$5.7tUS$2.6tUS$74.8b26.6x75.6x2.1x
Tue, 11 Feb 2025US$5.9tUS$2.6tUS$84.4b26.4x69.6x2.2x
Thu, 09 Jan 2025US$5.9tUS$2.9tUS$79.4b27.3x73.7x2x
Sat, 07 Dec 2024US$6.1tUS$2.9tUS$77.6b28.7x78.3x2.1x
Mon, 04 Nov 2024US$6.2tUS$2.9tUS$71.3b28.4x86.4x2.1x
Wed, 02 Oct 2024US$6.2tUS$2.8tUS$60.0b30.1x104x2.2x
Fri, 30 Aug 2024US$6.3tUS$2.8tUS$54.0b32.1x116.1x2.2x
Sun, 28 Jul 2024US$6.4tUS$2.8tUS$60.8b31.6x105x2.2x
Tue, 25 Jun 2024US$6.2tUS$2.8tUS$62.5b30.1x99.2x2.2x
Thu, 23 May 2024US$6.2tUS$2.8tUS$64.3b30.2x96.8x2.2x
Sat, 20 Apr 2024US$5.9tUS$2.8tUS$84.4b30x70.2x2.1x
Mon, 18 Mar 2024US$6.2tUS$2.8tUS$84.5b31.5x73.7x2.2x
Wed, 14 Feb 2024US$6.1tUS$2.8tUS$82.0b30.7x74.7x2.2x
Fri, 12 Jan 2024US$6.4tUS$2.8tUS$90.1b32x71.1x2.3x
Sun, 10 Dec 2023US$6.0tUS$2.8tUS$91.4b29.4x65.2x2.1x
Tue, 07 Nov 2023US$5.7tUS$2.8tUS$86.7b26.2x66.3x2x
Thu, 05 Oct 2023US$5.8tUS$2.8tUS$98.3b26.7x59.2x2.1x
Sat, 02 Sep 2023US$6.1tUS$2.8tUS$98.7b27.4x61.9x2.2x
Mon, 31 Jul 2023US$6.1tUS$2.7tUS$115.6b28x52.9x2.2x
Wed, 28 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.4x2.2x
Fri, 26 May 2023US$5.9tUS$2.7tUS$110.9b24x53x2.2x
Sun, 23 Apr 2023US$6.0tUS$2.5tUS$117.6b24.9x51x2.4x
Price to Earnings Ratio

51x


Total Market Cap: US$6.0tTotal Earnings: US$117.6bTotal Revenue: US$2.5tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.0x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market3.42%
Healthcare-0.18%
Life Sciences3.71%
Healthtech3.51%
Biotech1.98%
Medical Equipment0.50%
Healthcare Services-0.58%
Pharma-2.61%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.5x.
    • Analysts are expecting annual earnings growth of 16.1%, which is higher than its past year's earnings growth of 7.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 50% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RVMD Revolution MedicinesUS$152.5457.7%
+US$11.1b		321.4%PB18.5x
TMO Thermo Fisher ScientificUS$531.675.6%
+US$10.5b		21.7%PE29.5x
UNH UnitedHealth GroupUS$314.052.6%
+US$7.3b		-46.3%PE23.6x
BSX Boston ScientificUS$64.613.3%
+US$3.0b		-32.2%PE33.1x
MDLN MedlineUS$47.938.1%
+US$2.9b		n/aPE33.6x

Latest News

LLY
US$905.03
Eli Lilly
7D
-5.1%
1Y
23.2%
RVMD
US$152.54
Revolution Medicines
7D
57.7%
1Y
321.4%
CVS
US$74.99
CVS Health
7D
-4.8%
1Y
9.4%
JNJ
US$238.67
Johnson & Johnson
7D
-1.1%
1Y
55.1%
TMO
US$531.67
Thermo Fisher Scientific
7D
5.6%
1Y
21.7%
MRK
US$117.90
Merck
7D
-4.3%
1Y
54.2%
UNH
US$314.05
UnitedHealth Group
7D
2.6%
1Y
-46.3%

UNH: Medicare Policy Debate Will Support Post 2026 Earnings Resilience

Analysts have modestly revised their UnitedHealth Group price targets higher, with adjustments framed around slightly stronger long term profit margin assumptions, a small uptick in expected revenue growth, and mixed commentary on future margin pressure and policy risks. Analyst Commentary Recent research on UnitedHealth Group points to a split between caution around policy and margin headwinds and a more constructive stance on long term earnings power and capital deployment.
ABBV
US$208.42
AbbVie
7D
-1.5%
1Y
21.4%
ABT
US$101.56
Abbott Laboratories
7D
-1.9%
1Y
-21.7%
BNTX
US$99.47
BioNTech
7D
8.0%
1Y
1.2%
HCA
US$488.58
HCA Healthcare
7D
-3.3%
1Y
47.6%

HCA: Georgia Medicaid SDP And AI Efficiency Efforts Will Shape Future Upside

Analysts have lifted their average HCA Healthcare price target by $50, pointing to factors such as CMS approval of Georgia's $1.9b Medicaid SDP program and expectations that AI driven efficiency gains could support higher valuation multiples over time. Analyst Commentary Recent Street research around HCA Healthcare clusters around two themes: how the Georgia Medicaid SDP approval could support earnings and how AI related efficiency efforts could influence valuation multiples over time.
MDLN
US$47.93
Medline
7D
8.1%
1Y
n/a
SMMT
US$21.12
Summit Therapeutics
7D
12.3%
1Y
-8.4%
BSX
US$64.61
Boston Scientific
7D
3.3%
1Y
-32.2%

Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes

Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?
INSM
US$146.74
Insmed
7D
-8.4%
1Y
109.0%
ISRG
US$468.36
Intuitive Surgical
7D
1.3%
1Y
-2.7%

ISRG: Procedure Expansion And Sector Recovery Will Drive 2026 Upside

Analysts have adjusted Intuitive Surgical's price targets in a mixed but generally constructive way, with revisions ranging from cuts at UBS to $550 and $570 to higher targets at firms like Goldman Sachs at $714 and Bernstein at $740. These changes reflect updated views on growth, margins, and the valuation framework around a future P/E near 65.5x.